DENTSPLY SIRONA XRAY
- Market cap
- $1.9B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $3.6B
- −1% on a year ago
- Net margin
- −15.0%
- Free cash flow yield
- 7.6%
DENTSPLY SIRONA trades at 0.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $3.6B over the last twelve months, down 1% on a year earlier with a −15% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $947M+0% | $1B+3% | $953M−3% | $984M−4% | $951M+0% | $905M−11% | $879M−8% | $936M−5% | $904M−5% | $961M+6% | $880M+0% | $898M−4% | |
| Cost of revenue | $452M+3% | $490M+5% | $447M−3% | $473M−1% | $456M+1% | $459M−6% | $413M−8% | $446M−6% | $463M+2% | $518M+13% | $453M+10% | $405M−9% |
| Gross profit | $495M−3% | $522M+1% | $506M−3% | $511M−7% | $495M+0% | $446M−15% | $466M−8% | $490M−4% | $441M−11% | $443M−1% | $427M−8% | $493M+1% |
| R&D | $46M+12% | $43M+0% | $42M−9% | $41M−16% | $40M−13% | $42M−2% | $36M−14% | $37M−10% | $37M−8% | $40M−5% | $44M+22% | $45M+22% |
| SG&A | $372M−7% | $409M+2% | $415M−0% | $399M−4% | $390M+5% | $401M−2% | $358M−14% | $342M−14% | $355M−9% | $383M−5% | $351M−2% | $364M+6% |
| −$236M−81% | $73M+12% | $42M | $50M−38% | −$462M+96% | −$509M | $63M+50% | −$128M | −$218M−53% | −$139M−73% | −$35M | $82M | |
| Interest expense | $19M+36% | $20M+5% | $18M−10% | $17M−23% | $18M−5% | $16M−20% | $19M+6% | $24M+41% | $23M+28% | $22M+38% | $24M+26% | $22M−8% |
| Pre-tax income | −$250M−80% | $57M+613% | $31M | $34M−26% | −$478M+91% | −$523M | $44M+42% | −$153M | −$230M−52% | −$147M−72% | −$42M | $72M |
| $16M | −$15M | $14M | $38M | $17M+6% | −$95M+533% | $25M+79% | −$109M | $198M+1065% | −$2M−98% | −$32M | $36M | |
| Net income | −$266M−75% | $67M | $18M | −$4M | −$494M+86% | −$430M | $20M+11% | −$45M+1025% | −$427M−14% | −$146M−66% | −$10M | $37M |
| −$1.25−75% | $0.32 | $0.09 | −$0.02 | −$2.46+97% | −$2.16 | $0.10+11% | −$0.22+1000% | −$2.14−13% | −$0.73−66% | −$0.05 | $0.18 | |
| 211.8M−1% | 209.9M−3% | 208.5M−3% | 205.6M−4% | 201M−5% | 198.7M−5% | 199.8M−4% | 199.3M−3% | 199.5M−1% | 199.7M+1% | 199.9M+0% | 200.5M+1% |
EPS, diluted: 10 periods, Q4 FY08 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 14 periods, Q4 FY08 to Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY17 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest DENTSPLY SIRONA's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| XRAYDENTSPLY SIRONA | $1.9B | n/m | 34.2× | 0.5× | −1% | −15.0% | |
| LMATLemaitre Vascular | $1.9B | 29.6× | 42.0× | 7.4× | +12% | 25.0% | |
| INSPInspire Medical Systems | $2.1B | 15.4× | 58.0× | 2.3× | +4% | 15.0% | |
| UFPTUFP Technologies | $2.3B | 31.9× | 25.6× | 3.6× | +7% | 11.4% | |
| EYENational Vision | $1.5B | 30.6× | 53.3× | 0.7× | +8% | 2.5% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| ATRCAtriCure | $3B | 281× | 58.4× | 5.3× | +14% | 1.9% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| WRBYWarby Parker | $3.2B | 370× | 366× | 3.5× | +11% | 0.8% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| Peer median | $1.7B | 34.4× | 47.7× | 3.4× | +11% | 7.3% |
Investors who own it
Investors we follow who held DENTSPLY SIRONA at the end of Jun 30, 2026, from their 13F filings.
- Cathie WoodARK Investment Management0.0% of portfoliotrimmed
More on DENTSPLY SIRONA
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .